Review: Improving outcomes for patients with Burkitt lymphoma and HIV

AIDS Patient Care and STDs

Volumn 22, Issue 3, 2008, Pages 175-187

  Blinder, Victoria S ^a   Chadburn, Amy ^a   Furman, Richard R ^a   Mathew, Susan ^a   Leonard, John P ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; IFOSFAMIDE; MESNA; METHOTREXATE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TENIPOSIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOPHENOTYPING; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT; ADULT; B CELL LYMPHOMA; CLASSIFICATION; FEMALE; IMMUNOTHERAPY; MALE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKITT LYMPHOMA; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, AIDS-RELATED; MALE; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 40749145268     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0124     Document Type: Review

References (46)

1. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337:805-809.
2. Cote TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: Incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997;73:645-650.
3. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyons: International Agency for Research on Cancer Press; 2001.
4. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004;104:3009-3020.
5. Surveillance Epidemiology and End Results Cancer Stat Fact Sheets. 2006. http://seer.cancer.gov
6. Peters BS, Beck EJ, Coleman DG, et al. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: The changing face of AIDS. BMJ 1991;302:203-207.
7. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007;370:59-67.
8. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276.
9. Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004;22:2177-2183.
10. Carbone A, Gloghini A. AIDS-related lymphomas: From pathogenesis to pathology. Br J Haematol 2005;130:662-670.
11. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430-4438.
12. International Collaboration on HIVaC. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-1830.
13. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-1654.
14. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 1980;68:486-491.
15. Ostronoff M, Soussain C, Zambon E, et al. Burkitt's lymphoma in adults: A retrospective study of 46 cases. Nouv Rev Fr Hematol 1992;34:389-397.
16. Ziegler JL, Bluming AZ, Morrow RH, Fass L, Carbone PP. Central nervous system involvement in Burkitt's lymphoma. Blood 1970;36:718-728.
17. Epstein MA, Achong B, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;283:702-703.
18. Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndromerelated lymphomas: Correlation with tumor morphology and primary site. Blood 1993;82:619-624.
19. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000;18:3707-3721.
20. Muller JR, Janz S, Goedert JJ, Potter M, Rabkin CS. Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. Proc Natl Acad Sci USA 1995;92:6577-6581.
21. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
22. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
23. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
24. Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Erratum in Ann Intern Med 2006;144:620. Summary for patients in Ann Intern Med 2005;143: I28; PMID: 16103466. Ann Intern Med 2005;143:265-273.
25. Magrath IT, Janus C, Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984;63:1102-1111.
26. Spina M, Simonelli C, Talamini R, Tirelli U. Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era. J Clin Oncol 2005;23:8132-8133; author reply 3-4.
27. Stebbing J, Mandalia S, Palmieri C, Nelson M, Gazzard B, Bower M. Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2005;23:8538-40; author reply 40-41.
28. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461-2470.
29. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Erratum appears in Ann Oncol 2002;13:1961 Note: Norbert, P [corrected to Pescosta, N]. Ann Oncol 2002;13:1264-1274.
30. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of Cancer and Leukemia Group B Study 9251. Cancer 2004;100:1438-1448.
31. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
32. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925-934.
33. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196-1205.
34. McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol 1991;9:941-946.
35. Astrow AB, Tarabay G, Salerno VE, et al. Long-term survival in patients with human immunodeficiency virus-associated small non-cleaved cell lymphoma: The role for short course intensive chemotherapy. Hematol Oncol 2003;21:131-40.
36. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94:1492-1499.
37. Oriol A, Ribera J-M, Esteve J, et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 2003;88:445-453.
38. Gökbuget N, Arnold R, Buechner T. Intensification of induction and consolidation improves only subgroups of adult ALL: Analysis of 1200 patients in GMALL study 05/93 [abstract]. Blood 2001;98:802a.
39. Oriol A, Ribera J-M, Brunet S, del Potro E, Abella E, Esteve J. Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 2005;90:990-992.
40. Galicier L, Gérard L, Fieschi C, et al. Intensive chemotherapy (LMB-86 regimen) for AIDS-related Stage IV Burkitt's lymphoma/leukemia. In: Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; 2007.
41. Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol 1986;4:847-858.
42. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580.
43. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-1543.
44. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-4128.
45. Dunleavy K, Healey Bird BR, Pittaluga S, et al. Efficacy and toxicity of dose-adjusted EPOCH-rituximab in adults with newly diagnosed Burkitt lymphoma. J Clin Oncol 2007;25:18S (June 20 Suppl):8035.
46. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 2002;99:2685-2693.